Clinical trial · Interventional
Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma
A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Radical Treatment of Primary Hepatic Carcinoma
NCT03178929CI-TRIAL-00028023unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to explore the effect of SAMe on recurrence after radical treatment of Primary liver cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Liver Cancer | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| S-Adenosyl Methionine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- S-Adenosyl Methionine Treatment
- description
- Patients will be treated with S-Adenosyl Methionine treatment after radical treatment. 2000mg, po
- interventionNames
- Drug: S-Adenosyl Methionine
- type
- NO_INTERVENTION
- label
- control group
- description
- Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
Primary outcomes (1)
- measure
- Time to tumor recurrence
- timeFrame
- 2 years
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient must sign the informed consent prior to the beginning of any study-related procedures; * Patients diagnosed of Primary liver cancer; * BCLC Stage：Stage 0、Stage A; * Accept radical treatment; Exclusion Criteria: * With any other anti-cancer treatment before or after the surgery; * Patients with extrahepatic metastasis; * Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction; * Subjects accepting other trial drugs or participating in other clinical trials; * Female with pregnancy or during the lactation period.
References
Publications (0)
Data not yet available
No reference posted for this study.